Literature DB >> 9723576

Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil.

F L Andrade1, J M Annichino-Bizzacchi, S T Saad, F F Costa, V R Arruda.   

Abstract

The prevalence of the prothrombin gene variant (allele 20.210 A), factor V Leiden mutation, and homozygosity for transition 677C-->T in the methylenetetrahydrofolate reductase (MTHFR) gene was determined among patients with sickle cell disease (SCD). The group included 73 patients with median age of 32.3 years with a diagnosis of sickle cell anemia in 53 patients, hemoglobinopathy SC in 16 patients, and four with S/beta(0) thalassemia. Vascular complications such as ischemic stroke or deep vein thrombosis were diagnosed in nine patients. Heterozygosity for the prothrombin gene variant or factor V Leiden mutation was identified in four patients. However, only one patient, who developed ischemic stroke, was identified as a carrier of factor V Leiden mutation. None of the patients presented homozygosity for the thermolabile variant of the MTHFR. These data suggest a low clinical impact of inherited hypercoagulability risk factors in developing thrombosis, occlusive stroke, or mortality data among patients with SCD in Brazil.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723576     DOI: 10.1002/(sici)1096-8652(199809)59:1<46::aid-ajh9>3.0.co;2-#

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Prevalence of Factor V Leiden-G1691A and MTHFR-C677T Thrombosis Gene Modifier in Iron Deficiency Anemia: A Pathophysiological Effect in Indian Isolates.

Authors:  S K Pandey; S Pandey; R M Mishra; M Indurkar
Journal:  Indian J Clin Biochem       Date:  2016-05-18

Review 2.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

3.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30

4.  Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden.

Authors:  Zohreh Rahimi; Asad Vaisi-Raygani; Ronald L Nagel; Adriana Muniz
Journal:  J Thromb Thrombolysis       Date:  2007-07-11       Impact factor: 2.300

5.  Sickle cell disease and venous thromboembolism.

Authors:  Zohreh Rahimi; Abbas Parsian
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-24       Impact factor: 2.576

Review 6.  Sickle Cell Anemia and Its Phenotypes.

Authors:  Thomas N Williams; Swee Lay Thein
Journal:  Annu Rev Genomics Hum Genet       Date:  2018-04-11       Impact factor: 9.340

7.  A 19-year-old man with sickle cell disease presenting with spinal infarction: a case report.

Authors:  April Edwards; E Leila Jerome Clay; Valerie Jewells; Stacie Adams; Regina D Crawford; Rupa Redding-Lallinger
Journal:  J Med Case Rep       Date:  2013-08-23

8.  Factor V Leiden G1691A and prothrombin G20210A mutations among Palestinian patients with sickle cell disease.

Authors:  Fekri Samarah; Mahmoud A Srour
Journal:  BMC Hematol       Date:  2018-01-16

9.  Methylene tetrahydrofolate reductase gene mutation in sickle cell anaemia patients in Lagos, Nigeria.

Authors:  Oluwaseun Olabisi Adelekan; Ebele Ifeyinwa Uche; Taiwo Modupe Balogun; Vincent Oluseye Osunkalu; Akinsegun Abduljaleel Akinbami; Kamal Ayobami Ismail; Mulikat Adesola Badiru; Adedoyin Owolabi Dosunmu; Omolara Risqat Kamson
Journal:  Pan Afr Med J       Date:  2019-12-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.